NASDAQ · Shell Companies · USD

Oaktree Acquisition Corp. III Life Sciences (OACC) Stock Analysis

Oaktree Acquisition Corp. III Life Sciences (OACC) is a Shell Companies stock listed on NASDAQ and quoted in US Dollar.

OACC

$10.80

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OACC with… →

OACC Key Statistics

As of Sep 4, 2026

Trading

Open: $10.80
Previous Close: $10.80
Day's Range: 10.78–10.80
52-Week Range: 10.44–10.88
Volume: 140.60K

Valuation

Market Cap: $265.49M
P/E Ratio: 38.57
EPS (ttm): 0.28

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): $7.29M
Profit margin: 0.00%
Shares Outstanding: 19.78M
1-Year Return: +3.45%

Dividend and dates

Avg Volume: 28.92K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OACC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−0.40%+6.22%+2.08%

2024*20252026*

Year	Return
2026 (partial year)	+2.08%
2025	+6.22%
2024 (partial year)	−0.40%

As of September 4, 2026.

OACC Valuation vs Shell Companies Median

Median of 587 stocks

Metric	OACC	Shell Companies median	vs median
P/E	38.57	45.20	15% below
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 587 Shell Companies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Oaktree Acquisition Corp. III Life Sciences (OACC) carries a market capitalisation of $265.49M. It is classified in the Shell Companies industry, within the Financial Services sector.

OACC last closed at $10.80 on September 4, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $10.44 to $10.88. The latest close sits 3.45% above that 52-week low.

Financial Health

In fiscal 2025, Oaktree Acquisition Corp. III Life Sciences reported revenue of $0.00. The same year closed with net income of $7.29M. Profit margin runs at 0%. Trailing earnings per share are 0.28.

Valuation Assessment

OACC trades at a trailing price-to-earnings ratio of 38.57. That is 14.67% below the Shell Companies median of 45.2. 587 Shell Companies companies report these metrics, and the medians quoted come from that group.

Daily returns over the trailing 1 year annualize to a volatility of 4.3%. The trailing one-year price return is +3.45%. The stored price history starts on December 16, 2024, and the total return since then is +8.00%.

Growth & Income

No dividend is on file for OACC.

The record holds one complete calendar year, 2025, which returned +6.22%. 2026 is still running; the price is +2.08% year to date.

Peer Comparison

Oaktree Acquisition Corp. III Life Sciences (OACC) operates in the Shell Companies industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Oaktree Acquisition Corp. III Life Sciences	OACC	$265.49M	38.6
Churchill Capital Corp XI	CCXI	$746.38M	—
Churchill Capital Corp X	CCCX	$711.00M	—
Drugs Made In America Acquisition II Corp.	DMII	$647.83M	35.1

The Shell Companies industry average P/E ratio is 45.2x. Oaktree Acquisition Corp. III Life Sciences trades at a P/E of 38.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Shell Companies Stocks

CCXI

Churchill Capital Corp XI

$746.38M

CCCX

Churchill Capital Corp X

$711.00M

DMII

Drugs Made In America Acquisition II Corp.

$647.83M

BCSS

Bain Capital GSS Investment Corp.

$602.40M

EVAC

EQV Ventures Acquisition Corp. II

$602.01M

CXII

Churchill Capital Corp XII

$594.94M

View all Shell Companies stocks →

Popular Financial Services Stocks

BRK-B

Berkshire Hathaway Inc.

$1.08T

JPM

JPMorgan Chase & Co.

$953.33B

Visa Inc.

$700.27B

Mastercard Incorporated

$507.39B

BAC

Bank of America Corporation

$438.31B

View all Financial Services stocks →

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was founded in 1995 and is headquartered in Los Angeles, California.

Visit website →